Quick Answer
Denali Therapeutics Inc. reported Diluted EPS of $2.97 per share (loss) for fiscal year 2025.
Denali Therapeutics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.97 | -15.6% |
| 2024 | -$2.57 | -142.5% |
| 2023 | -$1.06 | +59.2% |
| 2022 | -$2.60 | -8.8% |
| 2021 | -$2.39 | -479.4% |
| 2020 | $0.63 | +130.4% |
| 2019 | -$2.07 | -430.8% |
| 2018 | -$0.39 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.74 | -17.5% | -2.8% |
| June 30, 2025 | -$0.72 | -22.0% | +7.7% |
| March 31, 2025 | -$0.78 | -14.7% | -23.8% |
| September 30, 2024 | -$0.63 | +12.5% | -6.8% |
| June 30, 2024 | -$0.59 | -145.4% | +13.2% |
| March 31, 2024 | -$0.68 | +15.0% | +5.6% |
| September 30, 2023 | -$0.72 | +14.3% | -155.4% |
| June 30, 2023 | $1.30 | +370.8% | +262.5% |
- Denali Therapeutics Inc. showed a decrease of -15.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2018–2025 period, Denali Therapeutics Inc.’s diluted eps has declined by 661.5% (from $0.39 per share (loss) to $2.97 per share (loss)).
- The most recent figure is from Denali Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: